Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677055 | PMC |
| http://dx.doi.org/10.4103/ijo.IJO_430_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.
BMC Ophthalmol
January 2025
Department of Vitreoretina, Akhand Jyoti Eye Hospital, Mastichak, Saran, Bihar, India.
Purpose: To compare the anatomical and visual outcomes in eyes with submacular hemorrhage (SMH) treated with a combination of ranibizumab (RBZ) either innovator or biosimilar (Razumab) and intravitreal perfluoropropane gas (CF).
Methods: Treatment naïve neovascular age related macular degeneration (n-AMD) patients with SMH were retrospectively analyzed. Patients received either innovator or biosimilar RBZ (3 loading doses followed by pro re nata regimen) and single injection of intravitreal CF.
A Tertiary Centre's Experience With Using Ranibizumab Biosimilar Compared to Aflibercept for Neovascular Age-Related Macular Degeneration: A Retrospective Study.
Cureus
December 2024
Ophthalmology, University Hospital of Wales, Cardiff, GBR.
Objective This study aims to evaluate the real-world efficacy of ranibizumab biosimilar (Ongavia), compared to aflibercept (Eylea), in the treatment of treatment-naïve neovascular age-related macular degeneration (nAMD) at a busy tertiary eye care centre. Methods A retrospective analysis of medical records from August 2022 to August 2024 was conducted, comparing treatment outcomes in treatment-naive nAMD patients who received either Ongavia or Eylea intravitreal anti-VEGF (vascular endothelial growth factor) injections under a treat-and-extend protocol. Initial and 12-month outcome measures post-treatment initiation were collected, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), prescribed treatment intervals, actual injection frequency, and the average total number of injections per eye over 12 months.
View Article and Find Full Text PDFEffect of panretinal photocoagulation versus intravitreal bevacizumab injection on optic disc microcirculation in patients with diabetic retinopathy.
Int J Retina Vitreous
December 2024
Retina Service, Farabi Eye Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin Square, Tehran, Iran.
Background: This retrospective study aimed to compare optic disc vasculature changes in 1 and 3 months after treatment with either panretinal photocoagulation (PRP) or Intravitreal bevacizumab (IVB) in patients with diabetic retinopathy.
Methods: A total of 50 eyes of 29 diabetic patients without severe complications were included in this comparative case series. Of these, twenty-eight eyes (15 patients) were assigned to the PRP group, while twenty-two eyes (14 patients) were treated with the biosimilar (IVB) (Stivant CinnaGen Co.
Shifting paradigms in retinopathy of prematurity treatment: The promise and challenges of biosimilars.
Clin Exp Ophthalmol
December 2024
Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital NHS Trust, London, UK.
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.
Clin Ophthalmol
November 2024
Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India.
Article Synopsis
- The study aimed to assess the visual and anatomical outcomes in diabetic macular edema (DME) patients who switched from intravitreal Aflibercept (IVI AFL) to biosimilar Ranibizumab (B-RBZ) due to financial reasons rather than efficacy issues.
- A total of 57 DME patients were observed, showing substantial improvement in visual acuity during treatment with Aflibercept and a slight decline after switching to Ranibizumab, but overall vision remained better than the initial baseline.
- The transition maintained anatomical stability in terms of central macular thickness and reduced subretinal and intra retinal fluid levels, indicating that biosimilar Ranibizumab is an effective and cost-efficient therapeutic option
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!